The approval of Roche’s Itovebi marks a pivotal moment in breast cancer care, with the potential to significantly alter treatment strategies for ER-positive, HER2-negative breast cancer patients with PIK3CA mutations. The regulatory green light indicates a promising shift in oncology, specifically
Ivan Kairatov is a renowned Biopharma expert with a wealth of experience in research and development, particularly at the intersection of technology and innovation in the field. Today, he shares insights into the groundbreaking research conducted at the University of Florida on developing a
In the rapidly evolving field of cancer epidemiology, understanding how race and ethnicity interact with cancer incidence and mortality is crucial. Ivan Kairatov, a biopharma expert with a strong background in research and development, sheds light on the implications of changing race data
Breast cancer remains a formidable adversary in the field of oncology, with radiotherapy serving as one of its most prevalent treatment modalities. Traditionally, radiotherapy is administered postoperatively to eliminate residual cancer cells and reduce the chances of relapse. Yet, the biological
The hidden might of tumors could hold the key to transforming brain cancer treatment. Aided by the latest research, scientists and healthcare professionals uncover how the physical forces exerted by cancerous growths could pave the way for novel therapeutic strategies. The Bridge Between Physics
In the quest to combat cancer, innovation sits at the heart of every breakthrough. The relentless pursuit of effective therapies has led scientists on a path filled with challenges and triumphs. As many grapple with diseases like intrahepatic cholangiocarcinoma, breast and bladder cancers,
